Company Snapshot
- Ticker
- EW
- Name
- EW
- Sector
- None
- Currency
- 0
- Relative Volume
- None
- Market Cap
- 48576876000.000000
- Volume
- 2,855,746
- Avg Volume (3M)
- 4,224,116
EW
EW
Last update recent
83.08
-1.16
(-1.38%)
Market Cap
48576876000.000000
Dividend Yield
0.00%
1Y Return
None%
Beta
None
Price & Moving Averages
Interactive chart with SMA overlays and intraday breadth.
Profitability
- Revenue
- 5883800000.000000
- EPS
- 2.33
- Dividend / Share
- None
- Total Dividends
- $0.00
- Dividend Yield
- 0.0%
- Net Income
- 1364500000.000000
- Net Margin
- 23.19%
- Payout Ratio
- 0.0%
- Qtly Growth YoY
- None
Valuation & Quality
- P/E
- 35.60
- Forward P/E
- None
- P/S
- 8.26
- P/B
- 4.76
- Beta
- None
- Debt / Equity
- 0.07
- Current Ratio
- 4.00
- Return on Equity
- 0.13%
- Return on Assets
- 0.10%
Technicals & Returns
- Distance vs 200 DMA
- 7.88%
- 200 DMA
- 77.01
- Distance vs 50 DMA
- 2.04%
- 50 DMA
- 81.42
- Return 1Y
- None%
- Return YTD
- None%
- Beta (Trailing)
- None
- Relative Volume
- None
Factor Lens
Plot valuation, momentum, or volume trends.
Seasonal Performance
Company Overview
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides the PASCAL and Cardioband transcatheter valve repair systems for minimally-invasive therapy. In addition, it offers surgical structural heart solutions, su Read more
- Name
- EW
- Industry
- Medical - Devices
- CEO
- Mr. Bernard J. Zovighian
- Employees
- 19,800
- IPO Date
- 2000-03-27
- Phone
- 949 250 2500
- Address
- None
- Website
- https://www.edwards.com
Dividend Yield
0.00%
TTM Distributions
$0.00
Latest News
Curated headlines from premium sources.
Should You Continue to Hold EW Stock in Your Portfolio?
Edwards Lifesciences leans on growth in Surgical Structural Heart, TAVR and TMTT, though macro pressures and litigation continue to weigh on margins.
Edwards Lifesciences Corporation (EW) Analyst/Investor Day Transcript
Edwards Lifesciences Corporation (EW) Analyst/Investor Day Transcript
Arrowstreet Capital Limited Partnership Sells 112,182 Shares of Edwards Lifesciences Corporation $EW
Arrowstreet Capital Limited Partnership reduced its position in Edwards Lifesciences Corporation (NYSE: EW) by 42.2% in the second quarter, according to the co…
Edwards Lifesciences Corporation $EW Shares Sold by Edgestream Partners L.P.
Edgestream Partners L.P. lowered its stake in Edwards Lifesciences Corporation (NYSE: EW) by 97.0% during the undefined quarter, according to its most recent F…
Avalon Global Asset Management LLC Takes Position in Edwards Lifesciences Corporation $EW
Avalon Global Asset Management LLC bought a new position in shares of Edwards Lifesciences Corporation (NYSE: EW) in the second quarter, according to the compa…
Edwards Lifesciences Reaffirms Strategy for Sustainable, Differentiated Growth at Annual Investor Conference
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) will outline its patient-focused strategy and share financial guidance during its annual inves…